Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $264.89 | 15 | 87.5% |
| Education | $37.69 | 2 | 12.5% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $245.80 | 14 | $0 (2024) |
| Astellas Pharma US Inc | $24.99 | 1 | $0 (2017) |
| Allergan, Inc. | $19.09 | 1 | $0 (2020) |
| Merck Sharp & Dohme Corporation | $12.70 | 1 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $108.05 | 6 | ABBVIE INC. ($108.05) |
| 2023 | $137.75 | 8 | AbbVie Inc. ($137.75) |
| 2020 | $19.09 | 1 | Allergan, Inc. ($19.09) |
| 2019 | $12.70 | 1 | Merck Sharp & Dohme Corporation ($12.70) |
| 2017 | $24.99 | 1 | Astellas Pharma US Inc ($24.99) |
All Payment Transactions
17 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/11/2024 | ABBVIE INC. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $18.85 | General |
| Category: ANTI-INFECTIVE | ||||||
| 10/07/2024 | ABBVIE INC. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $18.61 | General |
| Category: ANTI-INFECTIVE | ||||||
| 09/18/2024 | ABBVIE INC. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $18.83 | General |
| Category: ANTI-INFECTIVE | ||||||
| 05/25/2024 | ABBVIE INC. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $17.36 | General |
| Category: ANTI-INFECTIVE | ||||||
| 03/26/2024 | ABBVIE INC. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $16.76 | General |
| Category: ANTI-INFECTIVE | ||||||
| 01/30/2024 | ABBVIE INC. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $17.64 | General |
| Category: ANTI-INFECTIVE | ||||||
| 12/21/2023 | AbbVie Inc. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $16.68 | General |
| Category: ANTI-INFECTIVE | ||||||
| 10/18/2023 | AbbVie Inc. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $17.73 | General |
| Category: ANTI-INFECTIVE | ||||||
| 10/11/2023 | AbbVie Inc. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $16.54 | General |
| Category: ANTI-INFECTIVE | ||||||
| 05/23/2023 | AbbVie Inc. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $16.60 | General |
| Category: ANTI-INFECTIVE | ||||||
| 05/16/2023 | AbbVie Inc. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $16.55 | General |
| Category: ANTI-INFECTIVE | ||||||
| 05/09/2023 | AbbVie Inc. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $17.66 | General |
| Category: ANTI-INFECTIVE | ||||||
| 04/13/2023 | AbbVie Inc. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $19.35 | General |
| Category: ANTI-INFECTIVE | ||||||
| 04/04/2023 | AbbVie Inc. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $16.64 | General |
| Category: ANTI-INFECTIVE | ||||||
| 02/07/2020 | Allergan, Inc. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $19.09 | General |
| Category: ANTI-INFECTIVE | ||||||
| 11/22/2019 | Merck Sharp & Dohme Corporation | ZERBAXA (Drug) | Education | In-kind items and services | $12.70 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 05/15/2017 | Astellas Pharma US Inc | — | Education | In-kind items and services | $24.99 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 136 | 164 | $43,186 | $11,541 |
| 2022 | 5 | 181 | 238 | $76,672 | $19,587 |
| 2021 | 6 | 165 | 232 | $77,956 | $19,033 |
| 2020 | 5 | 179 | 246 | $69,814 | $20,305 |
All Medicare Procedures & Services
21 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 43 | 45 | $20,250 | $4,944 | 24.4% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 34 | 45 | $10,485 | $3,036 | 29.0% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 40 | 55 | $7,150 | $2,285 | 32.0% |
| 99221 | Initial hospital care with straightforward or low level of medical decision making, per day, if using time, at least 40 minutes | Facility | 2023 | 19 | 19 | $5,301 | $1,275 | 24.1% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 61 | 107 | $24,931 | $6,518 | 26.1% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 40 | 40 | $18,000 | $4,597 | 25.5% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 17 | 17 | $11,067 | $2,949 | 26.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 19 | 24 | $9,912 | $2,704 | 27.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 20 | 23 | $9,252 | $1,933 | 20.9% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 24 | 27 | $3,510 | $885.12 | 25.2% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 63 | 117 | $27,261 | $7,157 | 26.3% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 47 | 47 | $21,150 | $5,299 | 25.1% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 16 | 16 | $10,416 | $2,596 | 24.9% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 12 | 17 | $5,695 | $1,620 | 28.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 15 | 22 | $9,431 | $1,601 | 17.0% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 12 | 13 | $4,004 | $759.19 | 19.0% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 82 | 128 | $26,790 | $8,221 | 30.7% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 42 | 43 | $19,350 | $5,046 | 26.1% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 25 | 43 | $12,739 | $3,984 | 31.3% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 14 | 14 | $7,980 | $2,385 | 29.9% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 16 | 18 | $2,955 | $668.55 | 22.6% |
About Dr. Katherine Doktor, M.D
Dr. Katherine Doktor, M.D is a Infectious Disease healthcare provider based in Camden, New Jersey. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/11/2012. The National Provider Identifier (NPI) number assigned to this provider is 1386909752.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Katherine Doktor, M.D has received a total of $302.58 in payments from pharmaceutical and medical device companies, with $108.05 received in 2024. These payments were reported across 17 transactions from 4 companies. The most common payment nature is "Food and Beverage" ($264.89).
As a Medicare-enrolled provider, Doktor has provided services to 661 Medicare beneficiaries, totaling 880 services with total Medicare billing of $70,466. Data is available for 4 years (2020–2023), covering 21 distinct procedure/service records.
Practice Information
- Specialty Infectious Disease
- Location Camden, NJ
- Active Since 07/11/2012
- Last Updated 04/02/2019
- Taxonomy Code 207RI0200X
- Entity Type Individual
- NPI Number 1386909752
Products in Payments
- DALVANCE (Drug) $245.80
- AVYCAZ (Drug) $19.09
- ZERBAXA (Drug) $12.70
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Infectious Disease Doctors in Camden
Dr. Akinwale Olatosi, M.b.b.s, M.B.B.S
Infectious Disease — Payments: $41,876
Dr. Pola Dela Torre, Md, MD
Infectious Disease — Payments: $16,627
Dana Byrne, Md, MD
Infectious Disease — Payments: $1,885
Henry Fraimow, Md, MD
Infectious Disease — Payments: $1,513
Danielle Zambrano, Do, DO
Infectious Disease — Payments: $671.74
Lisa Pedroza, Md, MD
Infectious Disease — Payments: $650.52